Evidence map›Paper›PMID 40872957›Full record

ArticleVaccines2025

Protective Efficacy of Subunit Vaccine Expressing Rv0976c Against Tuberculosis.

Ziwei Zhou, Dan Chen, Fuzeng Chen, Wenxi Xu, Zhifen Pan, Zhihao Xiang, Xiaoxiao Gao, Yeyu Li, Fagang Zhong, Jun Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ziwei ZhouState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200433, China.
Dan ChenDepartment of Microbiology, School of Life Science, Fudan University, Shanghai 200433, China.
Fuzeng ChenState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200433, China.
Wenxi XuPrincess Margaret Cancer Center, Toronto, ON M5S 1A8, Canada.
Zhifen PanDepartment of Tuberculosis, The First Hospital of Jiaxing, Jiaxing University, Jiaxing 314001, China.
Zhihao XiangState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200433, China.
Xiaoxiao GaoState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200433, China.
Yeyu LiState Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200433, China.
Fagang ZhongXinjiang Academy of Agricultural and Reclamation Science, Shihezi 832000, China.
Jun LiuDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
Lu ZhangDepartment of Microbiology, School of Life Science, Fudan University, Shanghai 200433, China.ORCID 0000-0002-4858-0361

Funding

China's 13th Five Year Programs for the prevention and cure of great infectious diseases 2018ZX10731301-001-005National Key R&D Program of China No.2018YFD0500900
6 · The paper itself

Abstract

objectivesThe construction of subunit vaccines based on antigens that can induce strong cellular immunity is a widely accepted strategy to develop new tuberculosis vaccines. This study screens immunogens with potential for subunit vaccine development from seven candidate antigens and then verifies their vaccine efficacy.

designC57BL/6 mice were immunized subcutaneously with purified PPE19, PPE50, FadD21, Rv1505c, Rv1506c, Rv2035, and Rv0976c proteins formulated with Freund's adjuvant to evaluate both the antigen-specific Th1 cellular immune responses and IgG level. After the vaccination of mice with recombined pcDNA3.1 expressing Rv0976c, intravenous or aerosol infection with

resultsPurified PPE19, PPE50, FadD21, and Rv0976c proteins generated strong antigen-specific Th1 cellular immune responses in mice. Compared to Ag85A, Rv0976c also stimulated higher IgG antibody level in mice. In particular, Rv0976c stimulated high and specific IgG antibody levels in serum from TB patients. The vaccination of mice with DNA vaccines expressing Rv0976c, followed by intravenous challenge with Bacillus Calmette-Guerin (BCG) Pasteur or

conclusionsThese results indicated that Rv0976c was a better protective antigen. Future studies to combine Rv0976c with other antigens and evaluate its effectiveness as a booster of BCG or as a therapeutic vaccine are warranted.

Indexed as

antigensprotective efficacyRv0976csubunit vaccinestuberculosis

Identifiers

PMID40872957
PMCPMC12390289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.